Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

References

• Team N C P E R E. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)-China, 2020. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145–51. doi:10.3760/cma.j..0254-6450.2020.02.003. PMID: 32064853.
   PubMedGoogle Scholar
• Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5. PMID: 31986264.
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13. doi:10.1016/S0140-6736(20)30211-7. PMID: 32007143.
   PubMed Web of Science ®Google Scholar
• Chan JFW, Kok K-H, Zhu Z, Chu H, To KKW, Yuan S, Yuen K-Y. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221–36. doi:10.1080/22221751.2020.1719902. PMID: 31987001.
   PubMed Web of Science ®Google Scholar
• Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–74. doi:10.1016/s0140-6736(20)30251-8. PMID: 32007145.
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–63. doi:10.1126/science.abb2507. PMID: 32075877.
   PubMed Web of Science ®Google Scholar
• Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, Zhu H, Zhao W, Han Y, Qin C. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses. 2019;11(1):59. doi:10.3390/v11010059. PMID: 30646565.
   PubMed Web of Science ®Google Scholar
• Alharbi NK, Padron-Regalado E, Thompson CP, Kupke A, Wells D, Sloan MA, Grehan K, Temperton N, Lambe T, Warimwe G, et al. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine. 2017;35(30):3780–88. doi:10.1016/j.vaccine.2017.05.032. PMID: 28579232.
   PubMed Web of Science ®Google Scholar
• Munster VJ, Wells D, Lambe T, Wright D, Fischer RJ, Bushmaker T, Saturday G, van Doremalen N, Gilbert SC, de Wit E, et al. Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model. NPJ Vaccines. 2017;2(1):28. doi:10.1038/s41541-017-0029-1. PMID: 29263883.
   PubMedGoogle Scholar
• Ozharovskaia TA, Zubkova OV, Dolzhikova IV, Gromova AS, Grousova DM, Tukhvatulin AI, Popova O, Shcheblyakov DV, Scherbinin DN, Dzharullaeva AS, et al. Immunogenicity of different forms of Middle East respiratory syndrome S glycoprotein. Acta Naturae. 2019;11(1):38–47. doi:10.32607/20758251-2019-11-1-38-47. PMID: 31024747.
   PubMed Web of Science ®Google Scholar
• Chen Z, Zhang L, Qin C, Ba L, Yi CE, Zhang F, Wei Q, He T, Yu W, Yu J, et al. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol. 2005;79(5):2678–88. doi:10.1128/JVI.79.5.2678-2688.2005. PMID: 15708987.
   PubMed Web of Science ®Google Scholar
• Song F, Fux R, Provacia LB, Volz A, Eickmann M, Becker S, Osterhaus AD, Haagmans BL, Sutter G. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J Virol. 2013;87(21):11950–54. doi:10.1128/jvi.01672-13. PMID: 23986586.
   PubMed Web of Science ®Google Scholar
• Volz A, Kupke A, Song F, Jany S, Fux R, Shams-Eldin H, Schmidt J, Becker C, Eickmann M, Becker S, et al. Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein. J Virol. 2015;89(16):8651–56. doi:10.1128/jvi.00614-15. PMID: 26018172.
   PubMed Web of Science ®Google Scholar
• Lan J, Yao Y, Deng Y, Chen H, Lu G, Wang W, Bao L, Deng W, Wei Q, Gao GF, et al. Recombinant receptor binding domain protein induces partial protective immunity in Rhesus Macaques against Middle East respiratory syndrome coronavirus challenge. EBioMedicine. 2015;2(10):1438–46. doi:10.1016/j.ebiom.2015.08.031. PMID: 26629538.
   PubMed Web of Science ®Google Scholar
• Jiaming L, Yanfeng Y, Yao D, Yawei H, Linlin B, Baoying H, Jinghua Y, Gao GF, Chuan Q, Wenjie T. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Vaccine. 2017;35(1):10–18. doi:10.1016/j.vaccine.2016.11.064. PMID: 27899228.
   PubMed Web of Science ®Google Scholar
• Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO, Wise M, Patel A, Izmirly A, Aljuaid A, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med. 2015;7(301):301ra132. doi:10.1126/scitranslmed.aac7462. PMID: 26290414.
   PubMed Web of Science ®Google Scholar
• Yang Z, Kong W, Huang Y, Roberts A, Murphy BR, Subbarao KN, Abel GJ. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature. 2004;428(6982):561–64. doi:10.1038/nature02463. PMID: 15024391.
   PubMed Web of Science ®Google Scholar
• Deming D, Sheahan T, Heise M, Yount B, Davis N, Sims A, Suthar M, Harkema J, Whitmore A, Pickles R, et al. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med. 2006;3(12):e525. doi:10.1371/journal.pmed.0030525. PMID: 17194199.
   PubMed Web of Science ®Google Scholar
• Yasui F, Kai C, Kitabatake M, Inoue S, Yoneda M, Yokochi S, Kase R, Sekiguchi S, Morita K, Hishima T, et al. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J Immunol. 2008;181(9):6337–48. doi:10.4049/jimmunol.181.9.6337. PMID: 18941225.
   PubMed Web of Science ®Google Scholar
• Alharbi NK, Qasim I, Almasoud A, Aljami HA, Alenazi MW, Alhafufi A, Aldibasi OS, Hashem AM, Kasem S, Albrahim R, et al. Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels. Sci Rep. 2019;9(1):16292. doi:10.1038/s41598-019-52730-4. PMID: 31705137.
   PubMedGoogle Scholar
• Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, Reuschel EL, Robb ML, Racine T, Oh MD, et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis. 2019;19(9):1013–22. doi:10.1016/s1473-3099(19)30266-x. PMID: 31351922.
   PubMed Web of Science ®Google Scholar
• Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, Larkin BD, Andrews CA, Vogel L, Koup RA, Roederer M, et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial. Vaccine. 2008;26(50):6338–43. doi:10.1016/j.vaccine.2008.09.026. PMID: 18824060.
   PubMed Web of Science ®Google Scholar
• Poetsch JH, Dahlke C, Zinser ME, Kasonta R, Lunemann S, Rechtien A, Ly ML, Stubbe HC, Krähling V, Biedenkopf N, et al. Detectable vesicular stomatitis virus (VSV)-specific humoral and cellular immune responses following VSV-Ebola virus vaccination in humans. J Infect Dis. 2019;219(4):556–61. doi:10.1093/infdis/jiy565. PMID: 30452666.
   PubMed Web of Science ®Google Scholar
• Li J-X, Hou L-H, Meng F-Y, Wu S-P, Hu Y-M, Liang Q, Chu K, Zhang Z, Xu -J-J, Tang R, et al. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Glob Health. 2017;5(3):e324–e334. doi:10.1016/S2214-109X(16)30367-9. PMID: 28017642.
   PubMed Web of Science ®Google Scholar
• Fausther-Bovendo H, Kobinger GP. Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what’s important? Hum Vaccin Immunother. 2014;10(10):2875–84. doi:10.4161/hv.29594. PMID: 25483662.
   PubMed Web of Science ®Google Scholar
• See RH, Zakhartchouk AN, Petric M, Lawrence DJ, Mok CPY, Hogan RJ, Rowe T, Zitzow LA, Karunakaran KP, Hitt MM, et al. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J Gen Virol. 2006;87(3):641–50. doi:10.1099/vir.0.81579-0. PMID: 16476986.
   PubMed Web of Science ®Google Scholar
• Kim L, Liebowitz D, Lin K, Kasparek K, Pasetti MF, Garg SJ, Gottlieb K, Trager G, Tucker SN. Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial. JCI Insight. 2018;3(13):e121077. doi:10.1172/jci.insight.121077. PMID: 29997294.
   PubMed Web of Science ®Google Scholar
• Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, Cottrell CA, Becker MM, Wang L, Shi W, et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A. 2017;114(35):E7348–E7357. doi:10.1073/pnas.1707304114. PMID: 28807998.
   PubMed Web of Science ®Google Scholar
• Honda-Okubo Y, Barnard D, Ong CH, Peng B-H, Tseng CTK, Petrovsky N, Perlman S. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J Virol. 2015;89(6):2995–3007. doi:10.1128/JVI.02980-14. PMID: 25520500.
   PubMed Web of Science ®Google Scholar
• Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, Funkhouser W, Gralinski L, Totura A, Heise M, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol. 2011;85(23):12201–15. doi:10.1128/jvi.06048-11. PMID: 21937658.
   PubMed Web of Science ®Google Scholar
• Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, Peters CJ, Couch RB. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One. 2012;7(4):e35421. doi:10.1371/journal.pone.0035421. PMID: 22536382.
   PubMed Web of Science ®Google Scholar
• Agrawal AS, Tao X, Algaissi A, Garron T, Narayanan K, Peng BH, Couch RB, Tseng CT. Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother. 2016;12(9):2351–56. doi:10.1080/21645515.2016.1177688. PMID: 27269431.
   PubMed Web of Science ®Google Scholar
• Apostólico J, de S, Lunardelli VA, Coirada FC, Boscardin SB, Rosa DS. Adjuvants: classification, modus operandi, and licensing. J Immunol Res. 2016;2016:1459394. doi:10.1155/2016/1459394. PMID: 27274998.
   PubMed Web of Science ®Google Scholar